Eczema clinical trials

Explore recruiting eczema clinical trials.

Recruiting eczema studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Eczema trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis compared to no treatment: A prospective, controlled, split-body study

Norway, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)

Sweden, France, Czechia, Germany, Portugal, Belgium +3 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Atopic Dermatitis (COMPASS 2-AD)

Poland, Bulgaria, Germany, Czechia, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)

Spain, Italy, Romania

Phase III and phase IV (Integrated) EU CTIS Study details

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who Participated in Previous Afimkibart Clinical Trials

Italy, Poland, Germany, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

J2T-MC-KGBJ/DRM06-AD16 A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Spain, Poland, France, Germany, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Eczema trials by city

Eczema in Toronto Eczema in Vancouver Eczema in Montreal Eczema in Calgary Eczema in Edmonton Eczema in Ottawa Eczema in Winnipeg Eczema in Quebec City Eczema in Hamilton Eczema in Kitchener Eczema in London Eczema in Halifax Eczema in New York Eczema in Los Angeles Eczema in Chicago Eczema in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease